Search

This document provides a list of authors and their ORCID identifiers for a research article on cardiology and heart disease. The article focuses on the Public Assistance - Paris Hospitals (AP-HP) and their research on coronary syndrome and cardiovascular health. The authors' ORCID identifiers are included for reference. The document also includes keywords related to the article's subject matter. [Extracted from the article]

Cardiology, Cardiovascular Diseases and Conditions, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure According to the news editors, the research concluded: "Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. Keywords: Cardiology; Cardiovascular Diseases and Conditions; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Heart Failure EN Cardiology Cardiovascular Diseases and Conditions Health and Medicine Heart Disease Heart Disorders and Diseases Heart Failure 603 603 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Fresh data on heart failure are presented in a new report. [Extracted from the article]

The article cites a study on the use of H strain of avian infectious bronchitis virus from the Netherlands as a vaccine. Researcher Gosse Bijlenga and collaborators at Intervet in England, the University of Delaware in the U.S. and the Animal Health Service in the Netherlands reported that the H strain of infectious bronchitis (IB) was one of the earliest live attenuated IB vaccines to be developed and has continued to be used in most parts of the world for almost 50 years. Bijlenga and associates published their study in the journal "Avian Pathology."

The article reports that Axonyx Inc., has announced that Marvin S. Hausman, has stepped down as CEO and that Gosse B. Bruinsma has been unanimously appointed by the board of directors to this position. Hausman will continue to serve as chairman of the board. Bruinsma joined Axonyx in 2000 as president of Axonyx Europe BV based in the Netherlands. In April 2001 Bruinsma was promoted to chief operating officer and in September 2003 he became president of the company. Hausman is one of the founding fathers of Axonyx that was started as a company dedicated to the pursuit of finding treatments for Alzheimer and other neurodegenerative diseases.

The article cites a study conducted by researcher Gosse Bijlenga and colleagues, which reviews the use of H strain of avian infectious bronchitis virus. The H strain of infectious bronchitis (IB) was one of the earliest live attenuated IB vaccines to be developed and has continued to be used in most parts of the world for almost 50 years. The use of H52 has, however, declined with the introduction of safe and highly efficacious inactivated IB vaccines. The study was published in the recent issue of the journal "Avian Pathology."

Reports the promotion of Gosse B. Bruinsma and Gerard Vlak as president and vice chairman of the board of directors, respectively, of Axonyx Inc. Effectivity of the promotion; Prior positions of Bruinsma in the company; Career background of Vlak; Comment of company CEO and chairman Marvin S. Hausman on Bruinsma's and Vlak's promotion.